Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177520 | 0.85 | SMN1; SMN2 (0.32) | SMN1; SMN2CYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL537606 | 0.77 | SMN1; SMN2 (0.37) | ALOX5APFEN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL537595 | 0.75 | SMN1; SMN2 (0.38) | ALOX5APFEN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL4173041 | 0.75 | SMN1; SMN2 (0.36) | ALOX5APFEN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL537532 | 0.74 | SMN1; SMN2 (0.35) | ALOX5APFEN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL537622 | 0.74 | SMN1; SMN2 (0.35) | ALOX5APFEN1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL3383842 | 0.73 | — | — | |
| SCHEMBL3381024 | 0.72 | FPR2 (0.32) | FPR2PROKR1 | |
| SCHEMBL13451291 | 0.72 | ALOX5AP (0.38) | ALOX5APFEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14364494 | 0.72 | FPR2 (0.32) | FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990336-B1 | PROCESS FOR PRODUCTION OF 5-ALKOXY-4-HYDROXYMETHYLPYRAZOLE COMPOUND | IHARA CHEMICAL IND CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-7812175-B2 | Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-12 | — | — | US | disclosed |
| US-20090036688-A1 | Process for Production of 5-Alkoxy-4-Hydroxymethylpyrazole Compound | IHARA CHEMICAL INDUSTRY CO., LTD (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1990336-A1 | PROCESS FOR PRODUCTION OF 5-ALKOXY-4-HYDROXYMETHYLPYRAZOLE COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036688-A1 | Process for Production of 5-Alkoxy-4-Hydroxymethylpyrazole Compound | CYP4F3, ADH5, CYP3A4 | FPR2 814/4885PROKR1 4566/4885ALOX5AP 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.